Mesoblast (ASX:MSB) set the price for its Ryoncil mesenchymal stromal cell therapy as it seeks to launch the product in the coming weeks, according to a Thursday Australian bourse filing.
Ryoncil is a mesenchymal stromal cell therapy approved by the US Food and Drug Administration on Dec. 18, 2024, as the only therapy for pediatric patients aged two months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease.
The firm said its commercial execution is underway, and it is engaging with the top 45 centers representing 80% of pediatric transplants in the US.
Mesoblast plans to further evaluate the immunomodulatory effects of Ryoncil on gastrointestinal inflammation in treating medically refractory pediatric Crohn's disease patients.
The company's shares rose past 2% in recent trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。